Earum Pharmaceuticals Limited IPO:  GMP, Price, Dates, and size

Rate this post

Earum Pharmaceuticals Ltd is set to debut in the stock market with an issue size ₹6.65 Cr. Earum Pharmaceuticals Ltd is an Ahmedabad-based firm that trades, markets, and distributes pharmaceutical formulation products. It contains 125 medication formulation items, such as multivitamins, gynecology pharmaceuticals, steroids, antibiotics, cerebral activator drugs, gastrointestinal drugs, and so on. It also trades active pharmaceutical ingredients (APIs) such as Amoxicillin Trihydrate IP, Levofloxacin Hemihydrate IP, and Albendazole IP. It features 24 third-party items that are marketed under the company’s brand name. South East Asia, Latin America, and Africa are among the countries where the corporation has a domestic and worldwide presence.

Earum Pharmaceuticals Ltd IPO Detail

IPO DateJun 21, 2019 to Jun 26, 2019
Listing DateJul 4, 2019
Face Value₹10 per share
Price₹36 per share
Lot Size3000 Shares
Total Issue Size1,848,000 shares(aggregating up to ₹6.65 Cr)
Issue TypeFixed Price Issue IPO
Listing AtBSE SME
Global Longlife Hospital IPO Details

Earum IPO Tentative Dates

Earum IPO opens on Jun 21, 2019, and closes on Jun 26, 2019.

EventTentative Date
Opening DateJun 21, 2019
Closing DateJun 26, 2019
Basis of AllotmentJul 1, 2019
Initiation of RefundsJul 2, 2019
Credit of Shares to DematJul 3, 2019
Listing DateJul 4, 2019
UPI Mandate Confirmation Cut-Off Time5.00 PM on the issue closing day

Company Overview 

Earum  is in the pharmaceutical industry, marketing, trading, and distributing pharmaceutical formulation products such as anti-biotic drugs, anti-malarial, anti-allergic, and anti-cold drugs, analgesic/anti-pyretic & anti-inflammatory drugs, dermatology products, cerebral activator drugs, neurological drugs, gastro intestinal drugs, steroids, gynaecology drugs, calcium, multivitamins, anti-oxidants, and injections. They provide around 125 pharmaceutical formulation items, 24 of which we market under our own brand name and 24 of which we outsource to third parties. They also trade active pharmaceutical ingredients (APIs) like Levofloxacin Hemihdrate IP, Albendazol IP, Amoxicillin Trihydrate IP, and others.

Industry Overview

Trade disputes and fears about global economic prospects are dampening global growth. Borrowing costs for emerging and developing countries (EMDEs) have risen as a result of the strengthening of the US currency, greater financial market volatility, and growing risk premiums. Growth in industrialised countries has been diverging, with the United States benefiting from fiscal stimulus and the Eurozone seeing weaker growth. EMDE growth slowed to 4.2 percent in 2018, 0.3 percentage point lower than expected. Commodity exporters’ activity has slowed, owing primarily to country-specific obstacles.

World growth will slow from 3% in 2018 to 2.9% in 2019 and 2.8% in 2020-21. Growth in low-income countries (LICs) is strengthening, but LIC metals exporters are struggling owing to lower metal prices. In some EMDE regions, per capita growth would likely remain sluggish, hindering further poverty eradication.

Company Financials 

ParticularsFor the year/period ended (in Rs. Lakhs)
Total Assets2,741.002,052.881,108.45878.71
Total Revenue3,449.853,543.672,333.951,856.66
Profit After Tax86.5185.6515.989.76

Objects of the Issue

The Company intends to apply the Net Funds from the Offering to the following purposes:

  • To fulfil the requirements for working capital
  • General Corporate Goals
  • To cover the costs of the issue


  • Diversified Product Portfolio 
  • Experienced Promoter and Management team
  • Quality assurance


  • Dependence on a small number of products
  • High research and development cost

Earum Pharmaceuticals Ltd Lead Manager(s)

  • Hem Securities Limited 

Lead Manager Reports

  • IPO Lead Manager Performance Summary
  • IPO Lead Manager Performance Tracker

Company Contact Information

Earum Pharmaceuticals Limited

G1, Ground Floor, V R Complex,Near Sanathal Cross Road, SP Ring Road,

Sanathal, Ahmedabad, Gujarat-382210,

Phone: +91-79-48402525

Email: cs@earumpharma.com

Website: http://www.earumpharma.com/

Company Registrar

Bigshare Services Pvt Ltd

Phone: +91-22-6263 8200

Email: ipo@bigshareonline.com

Website: https://www.bigshareonline.com/


Please enter your comment!
Please enter your name here